Alison Tendler, MD
Ophthalmology · Sioux Falls, SDNPI 1205812328
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,062 of the $31,322 with a category attached, or 73.6%. AbbVie accounts for 69.1% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $8,732 and has fallen 73.0% since, to $2,358 in 2025. Among ophthalmology clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $195.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Carl Zeiss Meditec USA, Inc.$2K
- Carl Zeiss Meditec, Inc.$2K
- Lensar, Inc.$1K
- Eyepoint US, Inc.$1K
- Biotissue Holdings Inc.$775
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,6008%
- Speaking & faculty fees$23,06274%
- Travel & lodging$2,3738%
- Food & beverage$3,19410%
- Education$180%
- Gifts$190%
- Entertainment$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $21,645 |
| Carl Zeiss Meditec USA, Inc. | 3 | $1,923 |
| Carl Zeiss Meditec, Inc. | 2 | $1,861 |
| Lensar, Inc. | 1 | $1,400 |
| Eyepoint US, Inc. | 2 | $1,317 |
| Biotissue Holdings Inc. | 8 | $775 |
| Alcon | 16 | $483 |
| Galderma Laboratories, L.p. | 4 | $322 |
| Novartis | 9 | $311 |
| Dompe US, Inc. | 4 | $249 |
| Shire North American Group Inc | 3 | $201 |
| Merz North America, Inc. | 3 | $178 |
| Sun Pharmaceutical Industries Inc. | 8 | $135 |
| Bausch & Lomb Americas Inc. | 4 | $79 |
| Tarsus Pharmaceuticals, Inc. | 2 | $75 |
| Optos, Inc. | 1 | $56 |
| Oyster Point Pharma, Inc. | 2 | $52 |
| Ivantis, Inc | 2 | $51 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $44 |
| The Cameron-ehlen Group, Inc. | 2 | $27 |
| Merz Pharmaceuticals, LLC | 2 | $26 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $25 |
| Harrow Eye, LLC | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Medtronic | 1 | $18 |
| Align Ophthalmics LLC | 1 | $14 |
| NEW World Medical,inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$2,057
- VisuMax$2,057
- ARTEVO 800$2,057
- IOLMaster 700$1,846
- VERACITY SURGICAL$1,846
- LENSAR LASER SYSTEM$1,400
- DEXYCU$1,317
- Prokera$629
- AmnioGraft$629
- IOLMaster 500$211
- CALLISTO eye$211
- XEOMIN$138
- AcrySof IQ PanOptix UV IOL$117
- Oxervate$111
- XIIDRA$102
How this compares
$31,322 in reported general payments places this provider in the 90th percentile of 52 ophthalmology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 81 | $59,163 |
| XiidraLifitegrast | 42 | $38,559 |
| LotemaxLoteprednol Etabonate | 23 | $7,813 |
| Loteprednol Etabonate | 54 | $6,590 |
| Lotemax SmLoteprednol Etabonate | 24 | $5,984 |
| Fluorometholone | 66 | $3,909 |
| Cyclosporine | 12 | $3,222 |
| Doxycycline Hyclate | 95 | $2,686 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 59 | $567 |
| ErythromycinErythromycin Base | 54 | $546 |
| Prednisolone Acetate | 20 | $492 |
| ValacyclovirValacyclovir Hcl | 17 | $363 |
| Latanoprost | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $21,645 | $59,16381 claims |
| Bausch & Lomb Americas Inc.Xiidra | $79 | $38,55942 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate, Lotemax Sm | $44 | $20,388101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 ophthalmology providers in South Dakota.
Other ophthalmology in Sioux Falls
- Vance ThompsonSioux Falls$1.9M
- John BerdahlSioux Falls$1.2M
- Daniel TerveenSioux Falls$521K
- Tanner FergusonSioux Falls$49K
- Brent KramerSioux Falls$26K
- Jed AssamSioux Falls$18K
- Anthony MaiSioux Falls$8K
- Ryan GeraetsSioux Falls$7K
- Eric ThomasSioux Falls$7K
- Yujia ZhouSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.